These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20842590)

  • 21. Narrative review of palliative hypofractionated radiotherapy for high grade glioma.
    Saeed H; Tseng YD; Lo SS
    Ann Palliat Med; 2021 Jan; 10(1):846-862. PubMed ID: 33040565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
    Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology).
    Villani V; Anghileri E; Prosperini L; Lombardi G; Rudà R; Gaviani P; Rizzato S; Lanzetta G; Fabi A; Scaringi C; Pronello E; Simonetti G; Targato G; Pace A
    J Neurol; 2021 Aug; 268(8):2866-2875. PubMed ID: 33609154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
    Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
    J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A; Duran-Peña A; Bonnet C; Ducray F
    Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent high-grade glioma.
    Quant EC; Drappatz J; Wen PY; Norden AD
    Curr Treat Options Neurol; 2010 Jul; 12(4):321-33. PubMed ID: 20842591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
    Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
    Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of elderly patients with high-grade gliomas.
    Brandes AA; Monfardini S
    Semin Oncol; 2003 Dec; 30(6 Suppl 19):58-62. PubMed ID: 14765388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.
    Choi JW; Lee MM; Kim IA; Kim JH; Choe G; Kim CY
    J Korean Neurosurg Soc; 2008 Oct; 44(4):222-7. PubMed ID: 19096681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study.
    Garcia CR; Slone SA; Morgan RM; Gruber L; Kumar SS; Lightner DD; Villano JL
    Med Oncol; 2018 Aug; 35(10):136. PubMed ID: 30155806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.
    Soritau O; Tomuleasa C; Aldea M; Petrushev B; Susman S; Gheban D; Ioani H; Cosis A; Brie I; Irimie A; Kacso G; Florian IS
    J BUON; 2011; 16(2):282-9. PubMed ID: 21766499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
    Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
    J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
    Juratli TA; Schackert G; Krex D
    Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
    Gerber DE; Grossman SA; Zeltzman M; Parisi MA; Kleinberg L
    Neuro Oncol; 2007 Jan; 9(1):47-52. PubMed ID: 17108062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study.
    Jeyapalan S; Boxerman J; Donahue J; Goldman M; Kinsella T; Dipetrillo T; Evans D; Elinzano H; Constantinou M; Stopa E; Puthawala Y; Cielo D; Santaniello A; Oyelese A; Mantripragada K; Rosati K; Isdale D; Safran H;
    Am J Clin Oncol; 2014 Oct; 37(5):444-9. PubMed ID: 23388562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.